A comprehensive immunohistochemical analysis of 26 markers in
250 cases of serous ovarian tumors

J 2023

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors

NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela Kendall BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA et. al.

Basic information

Original name

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors

Authors

NEMEJCOVA, Kristyna (203 Czech Republic, guarantor), Adam SAFANDA (203 Czech Republic), Michaela Kendall BARTU KENDALL (203 Czech Republic), Romana MICHALKOVA (203 Czech Republic), Jana DROZENOVA (203 Czech Republic), Pavel FABIAN (203 Czech Republic), Jitka HAUSNEROVÁ (203 Czech Republic, belonging to the institution), Jan LACO (203 Czech Republic), Radoslav MATEJ (203 Czech Republic), Gabor MEHES (203 Czech Republic), Petr SKAPA (203 Czech Republic), Ivana STRUZINSKA (203 Czech Republic) and Pavel DUNDR (203 Czech Republic)

Edition

DIAGNOSTIC PATHOLOGY, LONDON, BMC, 2023, 1746-1596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30109 Pathology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.600 in 2022

RIV identification code

RIV/00216224:14110/23:00130655

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1186/s13000-023-01317-9

UT WoS

000941171800001

Keywords in English

Ovarian tumors; Tubo-ovarian tumors; High grade serous carcinoma; Low grade serous carcinoma; Immunohistochemistry

Abstract

V originále

BackgroundWe examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis.MethodsImmunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs.ConclusionWe provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.

Links

90233, large research infrastructures

Name: BBMRI.cz IV

Citovat

NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela Kendall BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Petr SKAPA, Ivana STRUZINSKA and Pavel DUNDR. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. DIAGNOSTIC PATHOLOGY. LONDON: BMC, 2023, vol. 18, No 1, p. 1-12. ISSN 1746-1596. Available from: https://dx.doi.org/10.1186/s13000-023-01317-9.

@article{2278170,
   author = {Nemejcova, Kristyna and Safanda, Adam and Bartu Kendall, Michaela Kendall and Michalkova, Romana and Drozenova, Jana and Fabian, Pavel and Hausnerová, Jitka and Laco, Jan and Matej, Radoslav and Mehes, Gabor and Skapa, Petr and Struzinska, Ivana and Dundr, Pavel},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1186/s13000-023-01317-9},
   keywords = {Ovarian tumors; Tubo-ovarian tumors; High grade serous carcinoma; Low grade serous carcinoma; Immunohistochemistry},
   language = {eng},
   issn = {1746-1596},
   journal = {DIAGNOSTIC PATHOLOGY},
   title = {A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors},
   url = {https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01317-9},
   volume = {18},
   year = {2023}
}

TY  - JOUR
ID  - 2278170
AU  - Nemejcova, Kristyna - Safanda, Adam - Bartu Kendall, Michaela Kendall - Michalkova, Romana - Drozenova, Jana - Fabian, Pavel - Hausnerová, Jitka - Laco, Jan - Matej, Radoslav - Mehes, Gabor - Skapa, Petr - Struzinska, Ivana - Dundr, Pavel
PY  - 2023
TI  - A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
JF  - DIAGNOSTIC PATHOLOGY
VL  - 18
IS  - 1
SP  - 1-12
EP  - 1-12
PB  - BMC
SN  - 17461596
KW  - Ovarian tumors
KW  - Tubo-ovarian tumors
KW  - High grade serous carcinoma
KW  - Low grade serous carcinoma
KW  - Immunohistochemistry
UR  - https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-023-01317-9
N2  - BackgroundWe examined a large cohort of serous tubo-ovarian tumors with 26 immunohistochemical markers, with the aim to assess their value for differential diagnosis and prognosis.MethodsImmunohistochemical analyses with 26 immunomarkers were performed on 250 primary tubo-ovarian tumors including 114 high grade serous carcinomas (HGSC), 97 low grade serous carcinomas (LGSC), and 39 serous borderline tumors (micropapillary variant, mSBT). The associations of overall positivity with clinicopathological characteristics were evaluated using the chi-squared test or Fisher's Exact test.ResultsWe found significantly different expression of p53, p16, ER, PR, PTEN, PAX2, Mammaglobin, RB1, Cyclin E1, stathmin, LMP2, L1CAM, CD44, and Ki67 in HGSCs compared to LGSCs. No significant differences were found between LGSC and mSBT. None of the other included markers (PAX8, ARID1A, HNF1B, Napsin A, CDX2, SATB2, MUC4, BRG1, AMACR, TTF1, BCOR, NTRK) showed any differences between the investigated serous tumors. Regarding the prognosis, only PR and stathmin showed a statistically significant prognostic meaning in LGSCs, with better overall survival (OS) and recurrence-free survival (RFS) in cases positive for PR, and worse outcome (RFS) for stathmin. None of the study markers showed prognostic significance in HGSCs.ConclusionWe provided an extensive immunohistochemical analysis of serous ovarian/tubo-ovarian tumors. Although we found some differences in the expression of some markers in HGSCs compared to LGSCs, only p53, p16, and Ki67 seem to be useful in real diagnostic practice. We also suggested the best discriminative cut-off for Ki67 (10% of positive tumor cells) for distinguishing HGSC from LGSC. We found prognostic significance of PR and stathmin in LGSCs. Moreover, the high expression of stathmin could also be of predictive value in ovarian carcinomas as target-specific anti-stathmin effectors are potential therapeutic targets.
ER  -

NEMEJCOVA, Kristyna, Adam SAFANDA, Michaela Kendall BARTU KENDALL, Romana MICHALKOVA, Jana DROZENOVA, Pavel FABIAN, Jitka HAUSNEROVÁ, Jan LACO, Radoslav MATEJ, Gabor MEHES, Petr SKAPA, Ivana STRUZINSKA and Pavel DUNDR. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors. \textit{DIAGNOSTIC PATHOLOGY}. LONDON: BMC, 2023, vol.~18, No~1, p.~1-12. ISSN~1746-1596. Available from: https://dx.doi.org/10.1186/s13000-023-01317-9.

Detailed Information on Publication Record